Recent studies have associated GPCRs, particularly the prostanoid receptor family, including EP receptor 1, EP2, EP3, and EP4, with cancer immune evasion, where PGE2, the most prevalent prostaglandin in cancers (Wu et al., 2019). This evidence concerns the gene PTGER3 and cancer.